Rationale and Design of Dual Antiplatelet Therapy in Patients with Coronary Multi-Vessel Disease (DAPT-MVD): A Multicenter, Randomized, Controlled Trial.

The optimal duration of dual antiplatelet therapy (DAPT) for patients with coronary multi-vessel disease (MVD) who have received drug-eluting stents (DES) remains unclear. The Dual Antiplatelet Therapy in Patients with Coronary Multi-Vessel Disease (DAPT-MVD) study is a multicenter, open-label, randomized controlled trial designed to assess the efficacy and safety of extended DAPT in MVD patients 12 months following DES implantation. We plan to enroll 8250 patients across approximately 100 sites in China. Participants will be randomized in a 1:1 ratio to receive either extended DAPT (75 mg clopidogrel plus 75-150 mg aspirin daily) or monotherapy (75-150 mg aspirin daily) beyond 12 months post-DES implantation. The follow-up period will last at least 12 months, with all potential endpoints adjudicated by a blinded Clinical Events Committee. The primary endpoint is major adverse cardiovascular and cerebrovascular events (MACCE), including cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. As of April 2024, a total of 8250 participants have been enrolled in the study. The mean age of the enrolled patients was 60.5 ± 8.8years, with 5753 (69.7%) being men. The DAPT-MVD study is the first large-scale trial to evaluate the efficacy and safety of prolonged DAPT with clopidogrel plus aspirin beyond 12 months after DES implantation in MVD patients. The trial will provide novel insights into the optimal duration of DAPT for MVD patients (ClinicalTrials. gov ID: NCT04624854. Registered on 10/27/2020).

Tian J ，Wang Z ，Wang Y ，Wang F ，Wang Y ，Zhao P ，Hou X ，Peng X ，Tian M ，Wang D ，Yu B ... -  《-》

Short-Term Dual Antiplatelet Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis.

Carvalho PEP ，Gewehr DM ，Nascimento BR ，Melo L ，Burkhardt G ，Rivera A ，Braga MAP ，Guimarães PO ，Mehran R ，Windecker S ，Valgimigli M ，Angiolillo DJ ，Bhatt DL ，Sandoval Y ，Chen SL ，Stone GW ，Lopes RD ... -  《-》

Fixed-Dose Antiplatelet Dual Combination in Patients with Coronary Artery Disease in Turkish Population: DAPT-TR.

Öz A ，Toprak K ，Aydin E ，Saraç İ ，Doğduş M ，Opan S ，Yenerçağ M ，Tascanov MB ，Kümet Ö ，Karaağaç M ，Özmen M ，Murat B ，Kertmen Ö ，Bekler Ö ，İnci S ，Huyut MA ，Özderya A ，Er F ，Duran M ，Ardahanlı İ ，Baş MM ，Güzel T ，Ceyhun G ，Özdemir İH ，Özen MB ，Gündüz R ，Erdoğan A ，Çetin İ ，Barış VÖ ，Yayla Ç ，Karaduman M ，Aşkın L ，Bekar L ，Tanrıverdi O ，Özkan E ，Yeşil E ，Çalışkan S ，Kuzu Z ，Uğuz B ，Böyük F ，Kunak AÜ ，Murat S ，Asil S ，Kayhan Ö ，Erdoğan E ，Duz R ，Katkat F ，Ekin T ，İbişoğlu E ，Ateş BN ，Ayça B ，Ergene AO ，Zoghi M ... -  《-》

Clinical Outcomes in Patients Treated With Biodegradable-Polymer Biolimus-Eluting Stents and 6 Months of Dual-Antiplatelet Therapy: The French eBiomatrix 6-Month DAPT Registry.

Lipiecki J ，Rampat R ，Piot C ，Benamer H ，Brunelle F ，Lefèvre T ，El Mahmoud R ，Varenne O ，Gommeaux A ，Malquarti V ，Angoulvant D ，Cruchon C ，Oldroyd K ，Spaulding C ... -  《-》

Low-dose colchicine for the prevention of cardiovascular events after percutaneous coronary intervention: Rationale and design of the COL BE PCI trial.

Patients with coronary artery disease (CAD) remain vulnerable to future major atherosclerotic events after revascularization, despite effective secondary prevention strategies. Inflammation plays a central role in the pathogenesis of CAD and recurrent events. To date, there is no specific anti-inflammatory medicine available with proven effective, cost-efficient, and favorable benefit-risk profile, except for colchicine. Initial studies with colchicine have sparked major interest in targeting atherosclerotic events with anti-inflammatory agents, but further studies are warranted to enforce the role of colchicine role as a major treatment pillar in CAD. Given colchicine's low cost and established acceptable long-term safety profile, confirming its efficacy through a pragmatic trial holds the potential to significantly impact the global burden of cardiovascular disease. The COL BE PCI trial is an investigator-initiated, multicenter, double-blind, event-driven trial. It will enroll 2,770 patients with chronic or acute CAD treated with percutaneous coronary intervention (PCI) at 19 sites in Belgium, applying lenient in- and exclusion criteria and including at least 30% female participants. Patients will be randomized between 2 hours and 5 days post-PCI to receive either colchicine 0.5 mg daily or placebo on top of contemporary optimal medical therapy and without run-in period. All patients will have baseline hsCRP measurements and a Second Manifestations of Arterial Disease (SMART) risk score calculation. The primary endpoint is the time from randomization to the first occurrence of a composite endpoint consisting of all-cause death, spontaneous non-fatal myocardial infarction, non-fatal stroke, or coronary revascularization. The trial is event-driven and will continue until 566 events have been reached, providing 80% power to detect a 21 % reduction in the primary endpoint taking a premature discontinuation of 15% into account. We expect a trial duration of approximately 44 months. The COL BE PCI Trial aims to assess the effectiveness and safety of administering low-dose colchicine for the secondary prevention in patients with both chronic and acute coronary artery disease undergoing PCI. ClinicalTrials.gov: NCT06095765.

De Cock E ，Kautbally S ，Timmermans F ，Bogaerts K ，Hanet C ，Desmet W ，Gurné O ，Vranckx P ，Hiltrop N ，Dujardin K ，Vanduynhoven P ，Vermeersch P ，Pirlet C ，Hermans K ，Van Reet B ，Ferdinande B ，Aminian A ，Dewilde W ，Guédès A ，Simon F ，De Roeck F ，De Vroey F ，Jukema JW ，Sinnaeve P ，Buysschaert I ... -  《-》